Figure 1 | Scientific Reports

Figure 1

From: Perioperative Administration of an Intravenous Beta-Blocker Landiolol Hydrochloride in Patients with Lung Cancer: A Japanese Retrospective Exploratory Clinical Study

Figure 1

Relapse-free survival period, hazard ratio, and 2-year relapse-free survival rate in the landiolol group and control group. CI, Confidence interval; RFS, Relapse-free survival. (a) Estimated based on Kaplan-Meier method. (b) Estimated based on Cox-Proportional Hazards Model assuming treatment groups to be single factors.

Back to article page